Citi Maintains a 'Neutral' on Regeneron Pharma (REGN); Doctors Consider Eylea as Replacement for Roche's Lucentis

Citi maintains a 'Neutral' on Regeneron Pharma (NASDAQ: REGN) price target of $68.

Analyst, Yaron Werber, suggested that recent channel checks indicate doctors are really considering switching to REGN's Eylea from Roche's (OTC: RHHBY) Lucentis, citing: 1) cut in price; 2) lower dosing amounts, but better potency; and 3) signs Eylea is working more effectively on certain patients.

Shares of REGN are trading near session highs, up $4.38 (+4.52%) to $101.24 (new 52-wk high). However, the stock has moved up from the mid-$30 level to over $100 in the past 52-wks.

For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.

Shares of Regeneron Pharma closed at $96.86 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Citi upgrades O-I Glass to Buy with $9 price target, opens 90-Day upside catalyst watch
• Benchmark Reiterates Buy Rating on NVIDIA (NVDA), Updates Estimates
• Ferrovial SA (FER:SM) (FRRVF) Reiterated at Buy by UBS on Winning Bid For Tennessee Project